IP Library › Granted Patent US 12,539,431
Granted Patent B2
US 12,539,431 · App. 18/608,887 · Granted Feb 3, 2026

System and methods for treating cancer cells with alternating polarity magnetic fields

Inventor: Vivek K. Sharma (San Ramon, CA)
Assignee: ASHA MEDICAL, INC.
A61N2/004A61J1/2006A61J1/2037A61J1/2072A61K45/06A61M5/19A61M39/14A61M39/24A61N2/002A61N2/02A61B5/055A61B6/032A61B6/037A61B6/50A61N2/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,539,431
App. No.
18/608,887
Granted
Feb 3, 2026
Kind
B2
Abstract

Systems and methods for destroying or inhibiting cancer cells and other rapidly-dividing cells including an alternating polarity (AP) magnetic field generator and one or more AP electromagnetic coil adapted to be coupled to at least a portion of a patient's body, and a controller to control the AP magnetic field generator and at least one AP electromagnetic coil and cause the field generator and coil to apply AP magnetic field having a frequency of 0.5-500 KHz and a field strength of 0.5-5 mT to the at least a portion of the patient's body area to achieve a desired inhibiting effect on cancer cells or other rapidly-dividing cells. Treatments provided by the system may be co-administered with an anti-cancer therapy such as a chemotherapy drug, a hormone therapy drug, targeted therapy drugs, immunotherapy drugs, an angiogenesis inhibitor drug, or tumor treatment field therapy.

Claims (64)

1 . A method of using magnetic fields to treat cancer cells in a target body area of a patient, comprising:

using a magnetic field therapy system comprising:

an alternating polarity (AP) magnetic field generator;

one or more AP electromagnetic coils electrically coupled to the AP magnetic field generator, wherein the one or more AP electromagnetic coils are energized by an electrical signal from the AP magnetic field generator to generate an AP magnetic field having at least a first frequency and a first field strength; and

a controller to control at least one of the first frequency and the first field strength of the AP magnetic field generated by the one or more AP electromagnetic coils;

coupling the one or more AP electromagnetic coils to at least a first portion of the patient's body;

generating an AP magnetic field having a first frequency of 0.5-500 kHz and a first field strength of 0.2-5 mT using the one or more AP electromagnetic coils;

applying the generated AP magnetic field to treat the cancer cells, wherein the generated AP magnetic field selectively affects the cancer cells to prevent metastasis of at least a portion of the cancer cells, while leaving non-cancer cells substantially unharmed.

2 . The method of claim 1 , wherein coupling the one or more AP electromagnetic coils to at least a first portion of the patient's body comprises using a retaining element selected from a garment and a bandage to maintain the one or more AP electromagnetic coils in close proximity to the at least a first portion of the patient's body.

3 . The method of claim 2 , wherein the cancer cells comprise at least one of:

brain cancer, and the retaining element is a hat;

breast cancer, and the retaining element is a wearable garment selected from a bra, a shirt, or a vest;

lung cancer, lung carcinoid tumors, thymic malignancies, tracheal tumors, pancreatic cancer, liver cancer, stomach cancer, kidney cancer, ovarian cancer, colon cancer and rectal cancer, and the retaining element is a wearable garment selected from a bra, a shirt, a vest, and a jacket;

a lower-body cancer selected from prostate cancer, ovarian cancer, colon cancer, and rectal cancer, and the retaining element is an undergarment;

skin cancer, and the retaining element is one of an adhesive bandage and a non-adhesive bandage; and

one of a throat, thyroid, mouth, nose, and salivary gland cancer, and the retaining element is selected from a neck cuff, a neck collar, and a scarf.

4 . The method of claim 1 , further comprising:

administering to the patient at least one additional anti-cancer therapy selected from a chemotherapy, a radiation therapy, an immunotherapy, a hormone therapy drug, a targeted therapy drug, an angiogenesis inhibitor drug, and tumor treatment field therapy.

5 . The method of claim 4 , wherein administering to the patient at least one additional anti-cancer therapy comprises administering the at least one additional anti-cancer therapy at one or more of:

a lower dosage than a dosage that would be administered in the absence of applying the generated AP magnetic field to the target body area; and

a reduced dosing frequency compared to the frequency that would be administered in the absence of applying the generated AP magnetic field to the target body area.

6 . The method of claim 1 wherein coupling the one or more AP electromagnetic coils to at least a first portion of the patient's body comprises coupling a plurality of AP electromagnetic coils to at least the target body area, wherein each electromagnetic coil in said plurality of electromagnetic coils is oriented so as to apply a desired AP magnetic field distribution in the target body area.

7 . The method of claim 1 , wherein generating an AP magnetic field comprises one or more of:

generating an AP magnetic field continuously for a first treatment period;

generating an AP magnetic field intermittently for a second treatment period in alternating on-time periods, followed by off time periods in which an AP magnetic field is not generated;

generating an AP magnetic field intermittently for one or more circadian treatment periods based on circadian rhythms of the patient; and

generating an AP magnetic field intermittently for one or more third treatment periods at defined times of day.

8 . The method of claim 1 , wherein generating an AP magnetic field comprises one or more of:

generating an AP magnetic field having a single first frequency of 0.5-400 kHz;

generating an AP magnetic field for a defined time period having a first frequency of 0.5-400 kHz that varies in a defined pattern; and

generating an AP magnetic field having multiple simultaneous frequencies of 0.5-400 kHz.

9 . The method of claim 8 , wherein generating an AP magnetic field for a defined time period having a first frequency of 0.5-400 kHz that varies in a defined pattern comprises at least one of:

generating an AP magnetic field in which the first frequency changes randomly at a defined rate;

generating an AP magnetic field in which the first frequency varies in a Gaussian distribution in one or more sub-ranges within the range of 0.5-400 kHz;

generating an AP magnetic field in which the first frequency varies in a non-Gaussian distribution in one or more sub-ranges within the range of 0.5-400 kHz.

10 . The method of claim 1 , wherein generating an AP magnetic field comprises generating an AP magnetic field having a first frequency within the range of 25-400 KHz.

11 . The method of claim 1 , wherein generating an AP magnetic field comprises generating an AP magnetic field having a first frequency within the range of 50-300 kHz and a first field strength within the range of 0.2-2 mT.

12 . The method of claim 1 , wherein generating an AP magnetic field comprises generating an AP magnetic field having a first frequency within the range of 0.5-150 kHz and a first field strength within the range of 0.2-2 mT.

13 . The method of claim 1 , wherein generating an AP magnetic field comprises generating an AP magnetic field in a burst mode defined by alternating on-time and off-time periods repeated at a second frequency, wherein each of the on-time periods of the second frequency comprises an AP magnetic field having the first frequency of 0.5-400 KHz.

14 . The method of claim 1 , wherein generating an AP magnetic field comprises generating an AP magnetic field having a first waveform, the method further comprising:

performing amplitude modulation of the first waveform of the generated AP magnetic field prior to the step of applying the generated AP magnetic field to the target body area.

15 . A system for treating cancer cells in a target body area of a patient comprising:

an alternating polarity (AP) magnetic field generator;

one or more AP electromagnetic coils electrically coupled to the AP magnetic field generator and adapted to be coupled to at least a first portion of the patient's body and energized by an electrical signal from the AP magnetic field generator to generate an AP magnetic field having at least a first frequency and a first field strength; and

a controller adapted to control the AP magnetic field generator and the one or more AP electromagnetic coils to cause the one or more AP electromagnetic coils to generate and apply to the at least a first portion of the patient's body an AP magnetic field having a frequency of 0.5-500 kHz and a field strength of 0.2-5 mT, wherein the AP magnetic field selectively affects the cancer cells to prevent metastasis of at least a portion of the cancer cells, while leaving non-cancer cells substantially unharmed.

16 . The method of claim 15 , wherein the one or more AP electromagnetic coils are adapted to be coupled to the at least a first portion of the patient's body by a retaining element during the application of the AP magnetic field, and wherein the cancer cells comprise at least one of:

brain cancer, and the retaining element is a wearable garment selected from a scarf and a hat;

breast cancer, and the retaining element is a wearable garment selected from a bra, a shirt, a vest, a jacket, a hat, an undergarment, and a bandage;

lung cancer, lung carcinoid tumors, thymic malignancies, tracheal tumors, pancreatic cancer, liver cancer, stomach cancer, kidney cancer, ovarian cancer, colon cancer and rectal cancer, and the retaining element is a wearable garment selected from a bra, a shirt, a vest, and a jacket;

a lower-body cancer selected from prostate cancer, ovarian cancer, colon cancer, and rectal cancer, and the retaining element is an undergarment;

skin cancer, and the retaining element is one of an adhesive bandage and a non-adhesive bandage; and

one of a throat, thyroid, mouth, nose, and salivary gland cancer, and the retaining element is selected from a neck cuff, a neck collar, and a scarf.

17 . The system of claim 15 , wherein the controller is adapted to cause the AP magnetic field generator and the one or more AP electromagnetic coils to apply the AP magnetic field to the target body area during a period in which the patient is being treated with one or more a chemotherapy drug, a radiation therapy, an immunotherapy drug, a hormone therapy drug, a targeted therapy drug, an angiogenesis inhibitor drug, and tumor treatment field therapy.

18 . The system of claim 15 , wherein the one or more AP electromagnetic coils comprises a plurality of AP electromagnetic coils each adapted to be coupled to a portion of the patient's body to obtain a desired magnetic field distribution in the patient's body.

19 . The system of claim 15 , wherein the controller comprises a timing control module to control the one or more AP electromagnetic coils to perform at least one of:

applying the AP magnetic field continuously to the at least a portion of the patient's body for a first treatment period;

applying the AP magnetic field intermittently for a second treatment period in alternating on time periods in which the AP magnetic field is applied to the at least a portion of the patient's body, followed by off time periods in which the AP magnetic field is not applied to the patient's body;

applying the AP magnetic field intermittently to the at least a portion of the patient's body for one or more circadian treatment periods based on circadian rhythms of the patient; and

applying the AP magnetic field intermittently to the at least a portion of the patient's body for one or more third treatment periods at defined times of day.

20 . The system of claim 15 , wherein the controller comprises a frequency control module to control the one or more AP electromagnetic coils to perform at least one of:

applying an AP magnetic field having a single frequency of 0.5-400 kHz to the at least a portion of the patient's body;

applying an AP magnetic field having a frequency of 0.5-400 kHz that varies in a defined pattern to the at least a portion of the patient's body;

applying an AP magnetic field having multiple simultaneous frequencies of 0.5-400 kHz to the at least a portion of the patient's body; and

applying an AP magnetic field having a bimodal magnetic field frequency distribution comprising a first variable AP magnetic field distribution that varies the magnetic field frequency between a first lower limit and a first upper limit and a second variable AP magnetic field distribution that varies the magnetic field frequency between a second lower limit and a second upper limit.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2024
From: SHARMA, VIVEK K.
To: ASHA MEDICAL, INC.
Reel/Frame 067772/0586 →
Continuity (6)
Continuation 18167865 · Feb 12, 2023
Continuation 17827984 · May 30, 2022
Continuation 17308019 · May 4, 2021
Continuation 16784239 · Feb 6, 2020
Provisional Application 62802685 · Feb 7, 2019
Related Publication 20240216710A1 · Jul 4, 2024
References Cited (149)
US 3756390A · Abbey et al. · 1973 [cited by applicant]
US 4781679A · Larkin · 1988 [cited by applicant]
US 5114411A · Haber et al. · 1992 [cited by applicant]
US 5637087A · O'Neil et al. · 1997 [cited by applicant]
US 6679827B2 · Sandstrom · 2004 [cited by applicant]
US 6868289B2 · Palti · 2005 [cited by applicant]
US 6926659B1 · Sandstrom · 2005 [cited by applicant]
US 6960184B2 · Willis et al. · 2005 [cited by applicant]
US 7016725B2 · Palti · 2006 [cited by applicant]
US 7104971B2 · Hjertman · 2006 [cited by applicant]
US 7519411B2 · Long · 2009 [cited by applicant]
US 7890183B2 · Palti et al. · 2011 [cited by applicant]
US 8005528B2 · Long · 2011 [cited by applicant]
US 8019414B2 · Palti · 2011 [cited by applicant]
US 8129694B2 · Balakin · 2012 [cited by applicant]
US 8175698B2 · Palti et al. · 2012 [cited by applicant]
US 8178859B2 · Balakin · 2012 [cited by applicant]
US 8188688B2 · Balakin · 2012 [cited by applicant]
US 8373145B2 · Balakin · 2013 [cited by applicant]
US 8406870B2 · Palti · 2013 [cited by applicant]
US 8447395B2 · Palti et al. · 2013 [cited by applicant]
US 8447396B2 · Palti et al. · 2013 [cited by applicant]
US 8465533B2 · Palti · 2013 [cited by applicant]
US 8614554B2 · Balakin · 2013 [cited by applicant]
US 8637818B2 · Balakin · 2014 [cited by applicant]
US 8690419B2 · Faccioli et al. · 2014 [cited by applicant]
US 8706258B2 · Nabors, Sr. et al. · 2014 [cited by applicant]
US 8706261B2 · Palti · 2014 [cited by applicant]
US 8710462B2 · Balakin · 2014 [cited by applicant]
US 8957396B2 · Balakin · 2015 [cited by applicant]
US 8965527B2 · Ruse et al. · 2015 [cited by applicant]
US 8992990B2 · Hua et al. · 2015 [cited by applicant]
US 9018601B2 · Balakin · 2015 [cited by applicant]
US 9023090B2 · Palti · 2015 [cited by applicant]
US 9023091B2 · Palti · 2015 [cited by applicant]
US 9039674B2 · Palti et al. · 2015 [cited by applicant]
US 9056203B2 · Palti et al. · 2015 [cited by applicant]
US 9081878B2 · Rofougaran · 2015 [cited by applicant]
US 9095270B2 · Flynn · 2015 [cited by applicant]
US 9157840B2 · Cho et al. · 2015 [cited by applicant]
US 9199043B2 · Chattaraj et al. · 2015 [cited by applicant]
US 9314649B2 · Balakin · 2016 [cited by applicant]
US 9440068B2 · Palti et al. · 2016 [cited by applicant]
US 9486512B2 · Kim et al. · 2016 [cited by applicant]
US 9486625B2 · Crawford et al. · 2016 [cited by applicant]
US 9636495B2 · Szasz et al. · 2017 [cited by applicant]
US 9655669B2 · Palti et al. · 2017 [cited by applicant]
US 9682247B2 · Susedik et al. · 2017 [cited by applicant]
US 9687668B2 · McKenna et al. · 2017 [cited by applicant]
US 9726647B2 · Walker et al. · 2017 [cited by applicant]
US 9750934B2 · Palti et al. · 2017 [cited by applicant]
US 9757582B2 · Sandstrom · 2017 [cited by applicant]
US 9757594B2 · Balakin · 2017 [cited by applicant]
US 9777265B2 · Subramaniam et al. · 2017 [cited by applicant]
US 9783808B2 · Lee et al. · 2017 [cited by applicant]
US 9789328B2 · Sandstrom · 2017 [cited by applicant]
US 9809810B2 · Subramaniam et al. · 2017 [cited by applicant]
US 9833617B2 · Travers et al. · 2017 [cited by applicant]
US 9885031B2 · Subramaniam et al. · 2018 [cited by applicant]
US 9999779B2 · Dougherty et al. · 2018 [cited by applicant]
US 10030039B2 · Ishikawa et al. · 2018 [cited by applicant]
US 10045910B2 · Mueller et al. · 2018 [cited by applicant]
US 10105491B2 · Gelblum et al. · 2018 [cited by applicant]
US 10124186B2 · McKenna et al. · 2018 [cited by applicant]
US 10161939B2 · Rao et al. · 2018 [cited by applicant]
US 10864139B2 · Genosar · 2020 [cited by applicant]
US 11027143B2 · Sharma · 2021 [cited by applicant]
US 11344739B2 · Sharma · 2022 [cited by applicant]
US 20010044643A1 · Litovitz · 2001 [cited by applicant]
US 20040267201A1 · Agerup · 2004 [cited by applicant]
US 20050090732A1 · Ivokov et al. · 2005 [cited by applicant]
US 20050209642A1 · Palti · 2005 [cited by applicant]
US 20060142748A1 · Foreman et al. · 2006 [cited by applicant]
US 20070129673A1 · Bassarab et al. · 2007 [cited by applicant]
US 20080171971A1 · DiPerna et al. · 2008 [cited by applicant]
US 20090038701A1 · Delmotte · 2009 [cited by applicant]
US 20100016651A1 · Sivo · 2010 [cited by applicant]
US 20100113959A1 · Pascual-Leone · 2010 [cited by applicant]
US 20100197993A1 · Vasishta · 2010 [cited by applicant]
US 20110054237A1 · Shapiro · 2011 [cited by applicant]
US 20120053555A1 · Ariagno et al. · 2012 [cited by applicant]
US 20120215281A1 · Neuman · 2012 [cited by applicant]
US 20130274707A1 · Wilmot et al. · 2013 [cited by applicant]
US 20160038753A1 · Chornenky et al. · 2016 [cited by applicant]
US 20160106996A1 · Sher-Rosenthal et al. · 2016 [cited by applicant]
US 20160120528A1 · Abtin · 2016 [cited by applicant]
US 20180147355A1 · Larsen et al. · 2018 [cited by applicant]
US 20180207439A1 · Cook · 2018 [cited by applicant]
US 20190167910A1 · Buchine et al. · 2019 [cited by applicant]
US 20200009017A1 · Sharma · 2020 [cited by applicant]
US 20200016424A1 · Tofani et al. · 2020 [cited by applicant]
US 20200222634A1 · Berry et al. · 2020 [cited by applicant]
AU 2019200616B2 · 2019 [cited by applicant]
CN 107427412B · 2020 [cited by applicant]
CN 112638446A1 · 2021 [cited by applicant]
DE 1815118A1 · 1970 [cited by applicant]
DE 102005038495A1 · 2007 [cited by applicant]
EP 1093826B1 · 2004 [cited by applicant]
EP 2665502B1 · 2020 [cited by applicant]
EP 3820548 · 2021 [cited by applicant]
EP 4257180A2 · 2023 [cited by applicant]
KR 101899449B1 · 2018 [cited by applicant]
WO 2020014157A1 · 2020 [cited by applicant]
International Search Report and Written Opinion dated Sep. 27, 2019, International Application No. PCT/US2019/040882 filed Jul. 9, 2018. [cited by applicant]
International Preliminary Report on Patentablility dated Jan. 12, 2021, International Application No. PCT/US2019/040882 filed Jul. 9, 2018. [cited by applicant]
Office Action dated Jul. 19, 2021, U.S. Appl. No. 16/504,325, filed Jul. 7, 2019. [cited by applicant]
Barbault et al., “Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach”. Journal of Experimental & Clinical Cance… [cited by applicant]
Binnewies et al., “Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy.” Nature Medicine 24, 5 (Apr. 2018): 541-550. [cited by applicant]
Bohnert, Julia “Effects of Time-Varying Magnetic Fields in the Frequency Range 1 KHz to 100 kHz upon the Human Body. Numerical Studies and Stimulation Experiment”, Karlsruhe Transactions on Biomedical Engineering, vol. … [cited by applicant]
Brahm et al., “The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review”. Cancers 2020, 12, 586. [cited by applicant]
Buckner et al., “Inhibition of Cancer Cell Growth by Exposure to a Specific Time-Varying Electromagnetic Field Involves T-Type Calcium Channels”, Plos One, DOI: 10.1371. [cited by applicant]
Crocetti et al., “Low Intensity and Frequency Pulsed Electromagnetic Fields Selectively Impair Breast Cancer Cell Viability”. PLoS ONE 8(9): e72944. [cited by applicant]
Delgado et al., “Embryological changes induced by weak, extremely low frequency electromagnetic fields”. J. Anat. (1982), 134, 3, pp. 533-551. [cited by applicant]
Duan et al., “Turning Cold into Hot: Firing up the Tumor Microenvironment”, Trends in Cancer, Jul. 2020, vol. 6, No. 7. [cited by applicant]
Filipovic et al., “Electromagnetic field investigation on different cancer cell lines”. Cancer Cell International 2014, 14:84. [cited by applicant]
Gera et al., “Tumor Treating Fields Perturb the Localization of Septins and Cause Aberrant Mitotic Exit”. PLoS ONE 10(5): e0125269. [cited by applicant]
Giladi et al., “Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells”. Scientific Reports, 5:18046. [cited by applicant]
Grasselly et al., “The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent”. Front. Immunol. 9:2100.doi: 10.3389/fimmu.2018.02100. [cited by applicant]
Kim et al., “Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis”. Oncotarget, vol. 7, No. 40. [cited by applicant]
Kirson et al., “Disruption of Cancer Cell Replication by Alternating Electric Fields,” Cancer Research, vol. 64, 3288-3295, May 1, 2004, American Assoc. for Cancer Research, US. [cited by applicant]
Kong et al., “A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy”, Int. J. Mol. Sci. 2017, 18, 1786. [cited by applicant]
Kozisnnik et al., “Magnetic fluid hyperthermia: Advances, challenges, and opportunity”. Int J Hyperthermia, 2013; 29 (8): 706-714. [cited by applicant]
Maffeo et al., “Lack of effect of weak low frequency electromagnetic fields on chick embryogenesis.”, J Anat. Dec. 1984; 139(Pt 4): 613-618. [cited by applicant]
Monache et al., “Inhibition of Angiogenesis Mediated by Extremely Low Frequency Magnetic Fields (ELF-MFs),” PLOS One, vol. 8, Issue 11, 1-11, Nov. 2013, PLOS, San Francisco, CA, US. [cited by applicant]
Newton et al., “Non-Invasive Radiofrequency Field Treatment of 4T1 Breast Tumors Induces T-cell Dependent Inflammatory Response”. Scientific Reports, 2018, 8:3474. [cited by applicant]
Nishimura et al., “Absence of reproductive and developmental toxicity in rats following exposure to a 20-KHz or 60-kHz magnetic field”, Regulatory Toxicology and Pharmacology, vol. 64, Issue 3, Dec. 2012, pp. 394-401. [cited by applicant]
Nishimura et al., “Lack of Teratological Effects in Rats Exposed to 20 or 60 KHz Magnetic Fields”, Birth Defects Research (Part B) 92:469-477 (2011). [cited by applicant]
Novocure, Inc., “Optunetm (NovoTTF-100A System) Patient Information and Operation Manual,” 1-45, Portsmouth, NH, US. [cited by applicant]
Novocure, Inc., “Instructions for Use, OPTUNETM (NovoTTF-100A System),” 1-27, Portsmouth, NH, US. [cited by applicant]
Ozen et al., “Low-frequency transient electric and magnetic fields coupling to child body”. Radiation Protection Dosimetry (2008), vol. 128, No. 1, pp. 62-67. [cited by applicant]
Porat et al., “Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)”, doi: 10.3791/55820. [cited by applicant]
Salari et al., “Towards non-invasive cancer diagnostics and treatment based on electromagnetic felds, optomechanics and microtubules”. arXiv:1708.08339 [physics.med-ph]. [cited by applicant]
Samoshree et al., “A Review on the Use of Magnetic Fields and Ultrasound for Non-invasive Cancer Treatment,” Journal of Advanced Research, 14, 97-111, Jun. 2018, Elsevier, B.V. [cited by applicant]
Tatarov et al., “Effect of Magnetic Fields on Tumor Growth and Viability”. Comparative Medicine, Aug. 2011, vol. 61, No. 4. [cited by applicant]
Vadala et al., “Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology”. Cancer Medicine 2016; 5(11):3128-3139. [cited by applicant]
Voloshin et al., Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. [cited by applicant]
Wenger et al., “A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred from Computational Modeling”. IEEE Reviews in Biomedical Engineering, 11, 195-207. [cited by applicant]
Zimmerman et al., “Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies”. Chin J Cancer Nov. 2013;32(11):573-81. [cited by applicant]
Office Action dated Oct. 20, 2020, U.S. Appl. No. 16/784,239, filed Feb. 26, 2020. [cited by applicant]
Notice of Allowance dated Jan. 26, 2021, U.S. Appl. No. 16/784,239, filed Feb. 26, 2020. [cited by applicant]
Notice of Allowance dated Feb. 10, 2021, U.S. Appl. No. 16/784,239, filed Feb. 26, 2020. [cited by applicant]
Baskin, D. et al., “Case Report: End-State Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device,” Frontiers in Oncology, 11, Jul. 2021, Article 708017. [cited by applicant]
Fuster, M., “Integrating Electromagnetic Cancer Stress With Immunotherapy: A Therapeutic Paradigm,” Frontiers in Oncology, 14:1417621, Aug. 2024. [cited by applicant]
Hambrade, S., et al., “Spinning Magnetic Field Patterns That Cause Oncolysis by Oxidative Stress in Glioma Cells,” Nature Portfolio (2023) 13:19264. [cited by applicant]
Helekar, S. et al., “EXTH-13. Potent Anticancer Effects of a New Wearable Noninvasive Oncomagnetic Device: Cellular Mechanisms of Action,” Neuro-Oncology, Nov. 2020, ii89. [cited by applicant]
Helekar, S., et al., “Selective Induction of Rapid Cytotoxic Effect in Glioblastoma Cells by Oscillating Magnetic Fields,” J. Cancer Research & Clinical Oncology, (2021) 147:3577-3589. [cited by applicant]
International Search Report and Written Opinion dated May 8, 2021, Intenational Application No. PCT/US2020/017365 filed Feb. 7, 2020. [cited by applicant]
Johns, S. et al., Glycocalyx Transduces Membrane Leak in Brain Tumor Cells Exposed to Sharp Magnetic Pulsing, Biophysical Journal, Nov. 21, 2023, 122, 4425-4439. [cited by applicant]
Sengupta, S. et al., “A Review On the Use of Magnetic Fields and Ultrasound for Non-Invasive Cancer Treatment,” Journal of Advanced Research 14 (2018), 97-111. [cited by applicant]